The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

The company reported flat overall revenues compared to Q4 2024 as gains in its imaging segment were offset by declines in its other businesses.

The firm's data and services revenues grew 26 percent to $81.3 million, while genomics revenues more than doubled to $252.9 million.

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.